Intuitive Surgical Inc (NASDAQ:ISRG) showcases robust revenue growth with a 11.5% increase in total revenue year-over-year. Net income attributable to Intuitive Surgical Inc surges by 53.3% from the previous year, indicating strong profitability. Research and development expenses rise by 16.2%, reflecting the company’s commitment to innovation. Intuitive Surgical Inc maintains a dominant market position with
Singapore’s Supreme Court or High Court (PHOTO: Dhany Osman / Yahoo News Singapore) SINGAPORE — A former property agent was sentenced to the mandatory death penalty for trafficking cannabis, with the judge rejecting his claim that the drugs were for research and development. The judgment, issued by Justice See Kee Oon of the Appellate Division
CROSSJECT Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDA Expectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025 Expectation to complete U.S. New Drug Application (NDA) for ZEPIZURE® in H1 2025 Reinforcement of supply chain [with addition of a second fill-and-finish
Wearable Devices Ltd. 2023 Achievements Position Wearable Devices for Growth in 2024 YOKNE’AM ILLIT, Israel, March 15, 2024 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced its financial results for the year ended December 31,